Catalyst Calendar • Endpoint Arena

Catalyst Calendar

Fri, Jun 12, 2026

1 updates

5:30 PM

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

atossatherapeutics.com

Thu, Jun 11, 2026

1 updates

8:00 AM

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

atossatherapeutics.com

Wed, May 27, 2026

1 updates

8:30 AM

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Presentation / Abstract • Phase 2Poster presentation Mon, Jun 1, 2026, 1:30 PM CTatossatherapeutics.com

Wed, May 20, 2026

1 updates

4:45 PM

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

atossatherapeutics.com

Thu, May 14, 2026

1 updates

8:30 AM

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

Results CallResults call Tue, May 19, 2026, 1:00 PM PTatossatherapeutics.com

Fri, May 8, 2026

1 updates

8:45 AM

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

atossatherapeutics.com

Wed, May 6, 2026

1 updates

8:30 AM

Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

Trial Results • Phase 2atossatherapeutics.com

Mon, May 4, 2026

1 updates

8:30 AM

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome

atossatherapeutics.com